RxDoctor Payments Data

Julie Haddy, MD

Nephrology · South Charleston, WVNPI 1629016647

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.9% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Amgen at 25.1% of the total. Reporting peaked in 2020 at $969 and has fallen 87.0% since, to $126 in 2025.

$2,998in general payments, 2019–2025

Across 157 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$752
  • AstraZeneca$627
  • Vifor Pharma, Inc.$483
  • Arbor Pharmaceuticals, Inc.$176
  • Otsuka America Pharmaceutical, Inc.$174
  • OPKO Pharmaceuticals, LLC$170
  • plus $616 from 9 others

What the payments were for

  • Food & beverage$2,84695%
  • Education$1525%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,998 in reported general payments places this provider in the 70th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$157,442
Medicare patients
428
Services billed
1,443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol14$12,189
JardianceEmpagliflozin15$11,279
Sevelamer Carbonate32$3,588
Calcium Acetate13$2,710
ProsolParenteral Amino Acid 20% No.112$1,227
Calcitriol45$863
Losartan Potassium80$708
Torsemide33$351
Valsartan11$316
Hydralazine Hcl30$309
Amlodipine Besylate49$278
Furosemide37$228
Carvedilol35$199
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide21$191
Lisinopril41$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$627$12,18914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 55 nephrology providers in West Virginia.

Other nephrology in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →